在阿尔茨海默氏病相关的视网膜病变中,通过饮食酸胆-EPA/DHA改善视网膜功能
Dhavamani Sugasini1, Jason C Park2, J Jason McAnany2
1Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Illinois, Chicago, IL, 60612, USA. Sugasini@UIC.edu.
Scientific reports
|June 6, 2023
概括
饮食中光酸胆 (LPC) 丰富的多可萨赫萨酸 (DHA) 和埃可萨酸 (EPA) 改善了视觉功能,并减少了阿尔茨海默氏症患者的粉样β.
科学领域:
- 神经科学是一个神经科学.
- 眼科医生 眼科 眼科
- 营养科学 营养科学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,视觉功能障碍往往在认知能力下降之前.
- 视网膜具有高度的多可萨赫萨酸 (DHA),其缺乏与视网膜疾病有关.
研究的目的:
- 调查是否通过饮食丰富视网膜DHA可以改善AD的5XFAD小鼠模型中的视网膜病变症状.
- 为了比较lysophosphatidylcholine (LPC) 与三糖醇 (TAG) 形式的DHA和eicosapentaenoic acid (EPA) 在视网膜输送中的疗效.
主要方法:
- 5XFAD小鼠在两个月内被食以LPC或TAG形式的DHA和EPA丰富的饮食.
- 我们量化了视网膜DHA和EPA水平.
- 电网光学被用来评估视觉功能 (a波和b波).
- 测量了视网膜中的粉样β水平.
主要成果:
- 5XFAD小鼠表现出较低的视网膜DHA比野生类型的 littermates.
- LPC-DHA/EPA饮食迅速使视网膜DHA正常化,并显著增加了EPA水平.
- 这种LPC-DHA/EPA饮食显著改善了电网膜学a波和b波功能.
- 视网膜粉样β水平在LPC-DHA/EPA饮食下降了大约50%.
- 在TAG-DHA/EPA饮食中,DHA/EPA水平和视觉功能只出现了适度的改善,粉样蛋白-β减少了17%.
结论:
- 在AD的小鼠模型中,以LPC形式的DHA和EPA的食丰富有效地增加了视网膜DHA和EPA水平.
- 通过LPC介导的DHA/EPA输送显示了改善视觉异常和减少与阿尔茨海默病相关的粉样蛋白病理的显著潜力.
相关概念视频
01:22Alzheimer's Disease: Treatment
224
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
224
01:26Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
01:26Alzheimer's Disease: Overview
536
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
536